Founded in 2016, AffyImmune is a clinical-stage biotechnology company that optimizes CAR T cells for the treatment of solid tumors using our Tune & Track platform. AIC100, our first product, spares healthy cells through our unique affinity-tuning, enhancing its safety and efficacy.
The initial indication for AIC100 is refractory thyroid cancer, which has a very poor prognosis and very few effective therapies. The antigen targeted by AIC100 is also overexpressed in a variety of additional cancers, including stomach, triple negative breast cancer and a number of others.
Company Details
- Employees
- 12
- Founded
- -
- Address
- 22 Strathmore Rd, Natick,massachusetts 01760,united States
- Phone
- (617) 699-1965
- Industry
- Biotechnology
- Website
- affyimmune.com
- HQ
- Natick, Massachusetts
Affyimmune Therapeutics Questions
Affyimmune Therapeutics's helpline number is (617) 699-1965
Affyimmune Therapeutics's website is affyimmune.com
Affyimmune Therapeutics's LinkedIn profile is https://www.linkedin.com/company/affyimmune
Affyimmune Therapeutics has
12 employees.
View email and phone details for 12
employees at Affyimmune Therapeutics.
Affyimmune Therapeutics's industry is
Biotechnology
Affyimmune Therapeutics's top competitors are
Pillar Biosciences Incorporated,
Vici Health Sciences,
Mustang Bio,
Vor Bio,
Elevatebio,
Replimune,
Bluerock Therapeutics,
Orna Therapeutics,
Minerva Biotechnologies,
Foghorn Therapeutics Inc..
Affyimmune Therapeutics's categories are Biotechnology
Affyimmune Therapeutics's founding year is 2016
